These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33649516)

  • 1. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
    Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
    Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
    Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
    JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
    Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
    Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
    J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer.
    Shiota M; Inoue R; Tashiro K; Kobayashi K; Horiyama S; Kanji H; Eto M; Egawa S; Haginaka J; Matsuyama H
    J Clin Pharmacol; 2023 Apr; 63(4):445-454. PubMed ID: 36484758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
    Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
    JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
    Hettel D; Sharifi N
    Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
    Wang Z; Deng T; Long X; Lin X; Wu S; Wang H; Ge R; Zhang Z; Wu CL; Taplin ME; Olumi AF
    PLoS One; 2020; 15(3):e0229754. PubMed ID: 32134978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
    Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
    Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
    Takahashi Y; Narita S; Shiota M; Miura M; Kagaya H; Kashima S; Yamamoto R; Nara T; Huang M; Numakura K; Saito M; Eto M; Habuchi T
    Eur J Clin Pharmacol; 2023 Jan; 79(1):89-98. PubMed ID: 36378297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
    Thomas L; Sharifi N
    Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
    Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
    Sabharwal N; Sharifi N
    Endocrinology; 2019 Sep; 160(9):2180-2188. PubMed ID: 31271415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
    Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
    Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zein J; Gaston B; Bazeley P; DeBoer MD; Igo RP; Bleecker ER; Meyers D; Comhair S; Marozkina NV; Cotton C; Patel M; Alyamani M; Xu W; Busse WW; Calhoun WJ; Ortega V; Hawkins GA; Castro M; Chung KF; Fahy JV; Fitzpatrick AM; Israel E; Jarjour NN; Levy B; Mauger DT; Moore WC; Noel P; Peters SP; Teague WG; Wenzel SE; Erzurum SC; Sharifi N
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2187-2193. PubMed ID: 31932420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
    Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
    Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.